FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs […]

[7-26-16] Today, the FDA has approved labeling changes for antibacterial drugs called fluoroquinolones, including an updated Boxed Warning, and advising that the serious side effects associated with […]

Safety Announcement [7-26-2013]   The U.S. Food and Drug Administration (FDA) is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, warning […]

Safety AnnouncementAdditional Information for Consumers and CaregiversAdditional Information for Healthcare ProfessionalsData Summary References Safety Announcement [04-07-2011] The U.S. Food and Drug Administration (FDA) is warning the public […]

For 2006 Safety information, please see the FDA Archive Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary References Safety Announcement [04-07-2011] The U.S. Food and […]

We conducted a drug utilization analysis of concomitant use of benzodiazepines with buprenorphine products being used for medication-assisted treatment (MAT), using the Prescription Behavior Surveillance System’s […]

[7/23/2020] To reduce the risk of death from opioid overdose, the U.S. Food and Drug Administration has made the following recommendations about the opioid reversal medicine, […]

Benzodiazepines are a class of medicines approved to treat generalized anxiety disorder, insomnia, seizures, social phobia, and panic disorder. Benzodiazepines are also used as premedication before […]

TOPIC: Benzodiazepine Drug Class: Drug Safety Communication – Boxed Warning Updated to Improve Safe Use AUDIENCE: Patient, Health Professional, Pharmacy ISSUE: The FDA is requiring the […]